These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35273656)

  • 1. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer.
    Duan Y; Cui C; Qiu C; Sun G; Wang X; Wang P; Ye H; Dai L; Shi J
    Dis Markers; 2022; 2022():6657820. PubMed ID: 35273656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
    Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
    Front Immunol; 2021; 12():698312. PubMed ID: 34489945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
    Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
    Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
    Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 9. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
    Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
    J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
    Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
    Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
    Wang J; Zhu M; Zhou X; Wang T; Zhang J
    J BUON; 2020; 25(5):2287-2292. PubMed ID: 33277847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
    Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
    Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
    Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
    Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.